The present disclosure provides radiopharmaceutical composition comprising copper-64 that performs as a targeted diagnostic PET-agent. The radiopharmaceutical composition disclosed herein has a short physical half-life of about 12.7 h.

The invention relates to products and methods that provide increased yields of certain radiopharmaceuticals.

A nuclear medicine infusion system (10) may be used to generate and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the infusion system includes a frame (30) that carries a radioisotope generator (52) that generates radioactive eluate via elution. The frame may also carry a beta detector (58) and a gamma detector (60). The beta detector can be positioned to measure beta emissions emitted from the radioactive eluate supplied by the generator. The gamma detector can be positioned to measure gamma emissions emitted from a portion of the radioactive eluate to evaluate a safety of the radioactive eluate delivered by the infusion system.

An infusion system may include a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to determine an activity of rubidium in the radioactive eluate based on the beta emissions measured by the beta detector and determine an activity of strontium in the radioactive eluate based on the gamma emissions measured by the gamma detector.

The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

A shielding assembly may be used in a nuclear medicine infusion system that generates and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the shielding assembly has multiple compartments each formed of a shielding material providing a barrier to radioactive radiation. For example, the shielding assembly may have a first compartment configured to receive a radioisotope generator that generates a radioactive eluate via elution, a second compartment configured to receive a beta detector, and a third compartment configured to receive a gamma detector. In some examples, the compartments are arranged to minimize background radiation emitted by the radioisotope generator and detected by the gamma detector to enhance the quality of the measurements made by the gamma detector.

A method for preparing a radiolabeled pharmaceutical. The method comprises passing a mixture that includes a radiolabeled compound through a column that contains an ion exchange resin to retain the radiolabeled compound on the ion exchange resin. At least a portion of the mixture passes through the column without being retained on the ion exchange resin. The method further comprises eluting the radiolabeled compound off the ion exchange resin using an eluting solution (e.g., a sodium chloride solution) to form a radiolabeled pharmaceutical.